{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:30:13Z","timestamp":1789684213529,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Beiersdorf(Thailand) Co., Ltd"},{"name":"Beiersdorf AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13555-025-01649-y","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:42:12Z","timestamp":1769013732000},"page":"1551-1565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Tolerability of 0.2% Thiamidol Cream for Facial Hyperpigmentation: A Randomized, Double-Blind, and Vehicle-Controlled Study"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03926845","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8296-3251","authenticated-orcid":false,"given":"Chinmanat","family":"Lekhavat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinda","family":"Rojanamatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkwan","family":"Suphannaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Kolbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"1649_CR1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1046\/j.1365-2133.2003.05419.x","volume":"149","author":"R Balkrishnan","year":"2003","unstructured":"Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572\u20137.","journal-title":"Br J Dermatol"},{"key":"1649_CR2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jaad.2017.05.009","volume":"77","author":"MBC Maymone","year":"2017","unstructured":"Maymone MBC, Neamah HH, Wirya SA, et al. The impact of skin hyperpigmentation and hyperchromia on quality of life: a cross-sectional study. J Am Acad Dermatol. 2017;77:775\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"1649_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdv.12049","volume":"27","author":"T Passeron","year":"2013","unstructured":"Passeron T. Melasma pathogenesis and influencing factors\u2014an overview of the latest research. J Eur Acad Dermatol Venereol. 2013;27(Suppl 1):5\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1649_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaad.2010.12.046","volume":"65","author":"VM Sheth","year":"2011","unstructured":"Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011;65:689\u201397.","journal-title":"J Am Acad Dermatol"},{"key":"1649_CR5","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1038\/jid.2011.109","volume":"131","author":"HY Kang","year":"2011","unstructured":"Kang HY, Suzuki I, Lee DJ, et al. Transcriptional profiling shows altered expression of wnt pathway- and lipid metabolism-related genes as well as melanogenesis-related genes in melasma. J Invest Dermatol. 2011;131:1692\u2013700.","journal-title":"J Invest Dermatol"},{"key":"1649_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cellsig.2017.09.004","volume":"40","author":"T Pillaiyar","year":"2017","unstructured":"Pillaiyar T, Manickam M, Jung SH. Recent development of signaling pathways inhibitors of melanogenesis. Cell Signal. 2017;40:99\u2013115.","journal-title":"Cell Signal"},{"key":"1649_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2133.2006.07210.x","volume":"155","author":"N Unver","year":"2006","unstructured":"Unver N, Freyschmidt-Paul P, Horster S, et al. Alterations in the epidermal-dermal melanin axis and factor XIIIa melanophages in senile lentigo and ageing skin. Br J Dermatol. 2006;155:119\u201328.","journal-title":"Br J Dermatol"},{"key":"1649_CR8","first-page":"20","volume":"3","author":"EC Davis","year":"2010","unstructured":"Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3:20\u201331.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1649_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaad.2011.06.001","volume":"65","author":"VM Sheth","year":"2011","unstructured":"Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011;65:699\u2013714.","journal-title":"J Am Acad Dermatol"},{"key":"1649_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1034\/j.1600-0749.2003.00029.x","volume":"16","author":"S Briganti","year":"2003","unstructured":"Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res. 2003;16:101\u201310.","journal-title":"Pigment Cell Res"},{"key":"1649_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.fsc.2011.05.010","volume":"19","author":"AM Rossi","year":"2011","unstructured":"Rossi AM, Perez MI. Treatment of hyperpigmentation. Facial Plast Surg Clin North Am. 2011;19:313\u201324.","journal-title":"Facial Plast Surg Clin North Am"},{"key":"1649_CR12","doi-asserted-by":"publisher","first-page":"7395","DOI":"10.1021\/acs.jmedchem.7b00967","volume":"61","author":"T Pillaiyar","year":"2018","unstructured":"Pillaiyar T, Namasivayam V, Manickam M, Jung SH. Inhibitors of melanogenesis: an updated review. J Med Chem. 2018;61:7395\u2013418.","journal-title":"J Med Chem"},{"key":"1649_CR13","first-page":"527","volume":"14","author":"AE Kheirieh","year":"2024","unstructured":"Kheirieh AE, Sharififar F, Ansari Dogaheh M, Dabaghzadeh F, Shamsi Meymandi S, Bakhshoudeh B. Evaluating the efficacy of Terminalia chebula Retz. 5% cream compared to hydroquinone 2% cream in the treatment of melasma. Avicenna J Phytomed. 2024;14:527\u201336.","journal-title":"Avicenna J Phytomed"},{"key":"1649_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2017.01.036","volume":"77","author":"S Chaowattanapanit","year":"2017","unstructured":"Chaowattanapanit S, Silpa-Archa N, Kohli I, Lim HW, Hamzavi I. Postinflammatory hyperpigmentation: a comprehensive overview: treatment options and prevention. J Am Acad Dermatol. 2017;77:607\u201321.","journal-title":"J Am Acad Dermatol"},{"key":"1649_CR15","first-page":"718","volume":"18","author":"KA Huerth","year":"2019","unstructured":"Huerth KA, Hassan S, Callender VD. Therapeutic insights in melasma and hyperpigmentation management. J Drugs Dermatol. 2019;18:718\u201329.","journal-title":"J Drugs Dermatol"},{"key":"1649_CR16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/DSS.0000000000000793","volume":"42","author":"L Imhof","year":"2016","unstructured":"Imhof L, Dummer R, Dreier J, Kolm I, Barysch MJ. A prospective trial comparing Q-switched ruby laser and a triple combination skin-lightening cream in the treatment of solar lentigines. Dermatol Surg. 2016;42:853\u20137.","journal-title":"Dermatol Surg"},{"key":"1649_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijwd.2017.01.004","volume":"3","author":"MK Trivedi","year":"2017","unstructured":"Trivedi MK, Yang FC, Cho BK. A review of laser and light therapy in melasma. Int J Womens Dermatol. 2017;3:11\u201320.","journal-title":"Int J Womens Dermatol"},{"key":"1649_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.12788\/j.sder.2016.060","volume":"35","author":"JY Li","year":"2016","unstructured":"Li JY, Geddes ER, Robinson DM, Friedman PM. A review of melasma treatment focusing on laser and light devices. Semin Cutan Med Surg. 2016;35:223\u201332.","journal-title":"Semin Cutan Med Surg"},{"key":"1649_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.02.022","volume":"69","author":"T Passeron","year":"2013","unstructured":"Passeron T. Long-lasting effect of vascular targeted therapy of melasma. J Am Acad Dermatol. 2013;69:e141\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"1649_CR20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jid.2018.01.019","volume":"138","author":"T Mann","year":"2018","unstructured":"Mann T, Gerwat W, Batzer J, et al. Inhibition of human tyrosinase requires molecular motifs distinctively different from mushroom tyrosinase. J Invest Dermatol. 2018;138:1601\u20138.","journal-title":"J Invest Dermatol"},{"key":"1649_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jid.2019.02.013","volume":"139","author":"C Arrowitz","year":"2019","unstructured":"Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L. Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to moderate melasma. J Invest Dermatol. 2019;139:1691-98.e6.","journal-title":"J Invest Dermatol"},{"key":"1649_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/ics.12694","volume":"43","author":"D Roggenkamp","year":"2021","unstructured":"Roggenkamp D, Dlova N, Mann T, et al. Effective reduction of post-inflammatory hyperpigmentation with the tyrosinase inhibitor isobutylamido-thiazolyl-resorcinol (Thiamidol). Int J Cosmet Sci. 2021;43:292\u2013301.","journal-title":"Int J Cosmet Sci"},{"key":"1649_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/ics.12626","volume":"42","author":"WG Philipp-Dormston","year":"2020","unstructured":"Philipp-Dormston WG, Vila Echague A, Perez Damonte SH, et al. Thiamidol containing treatment regimens in facial hyperpigmentation: an international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study. Int J Cosmet Sci. 2020;42:377\u201387.","journal-title":"Int J Cosmet Sci"},{"key":"1649_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030690","volume":"19","author":"T Mann","year":"2018","unstructured":"Mann T, Scherner C, Rohm KH, Kolbe L. Structure-activity relationships of thiazolyl resorcinols, potent and selective inhibitors of human tyrosinase. Int J Mol Sci. 2018;19:690.","journal-title":"Int J Mol Sci"},{"issue":"78\u201383","key":"1649_CR25","first-page":"83.e1","volume":"64","author":"AG Pandya","year":"2011","unstructured":"Pandya AG, Hynan LS, Bhore R, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(78\u201383):83.e1-2.","journal-title":"J Am Acad Dermatol"},{"key":"1649_CR26","first-page":"265","volume":"2","author":"N Ibraheem","year":"2012","unstructured":"Ibraheem N, Hasan MM, Khan RZ, Mishra PK. Understanding color models: a review. ARPN J Sci Technol. 2012;2:265\u201375.","journal-title":"ARPN J Sci Technol"},{"key":"1649_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/1523-1747.ep12616156","volume":"99","author":"IL Weatherall","year":"1992","unstructured":"Weatherall IL, Coombs BD. Skin color measurements in terms of CIELAB color space values. J Invest Dermatol. 1992;99:468\u201373.","journal-title":"J Invest Dermatol"},{"key":"1649_CR28","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/jdv.17344","volume":"35","author":"PB Lima","year":"2021","unstructured":"Lima PB, Dias JAF, Cassiano DP, et al. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial. J Eur Acad Dermatol Venereol. 2021;35:1881\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1649_CR29","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/jocd.16287","volume":"23","author":"V Vachiramon","year":"2024","unstructured":"Vachiramon V, Sakpuwadol N, Yongpisarn T, Anuntrangsee T, Palakornkitti P. Efficacy of isobutylamido thiazolyl resorcinol for prevention of laser-induced post-inflammatory hyperpigmentation: a randomized, controlled trial. J Cosmet Dermatol. 2024;23:2450\u20137.","journal-title":"J Cosmet Dermatol"},{"key":"1649_CR30","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1111\/jocd.14031","volume":"20","author":"W Disphanurat","year":"2021","unstructured":"Disphanurat W, Srisantithum B. Efficacy and safety of 0.15% isobutylamido thiazolyl resorcinol combined with hyaluronic acid vs 0.15% isobutylamido thiazolyl resorcinol or hyaluronic acid alone in melasma treatment: a randomized evaluator-blind trial. J Cosmet Dermatol. 2021;20:3563\u201372.","journal-title":"J Cosmet Dermatol"},{"key":"1649_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamadermatol.2016.1006","volume":"152","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Ayala-Cortes AS, Rodriguez-Arambula A, Hynan LS, Pandya AG. Interpretability of the modified melasma area and severity index (mMASI). JAMA Dermatol. 2016;152:1051\u20132.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01649-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:06:25Z","timestamp":1774371985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01649-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1649"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01649-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thiamidol is patented by Beiersdorf AG. The Thiamidol cream 0.2% samples and the study funding were provided by Beiersdorf (Thailand) Co., Ltd. Dr. Ludger Kolbe, an employee of Beiersdorf AG, Hamburg, Germany, contributed to the study\u2019s conceptualization, data curation, provision of resources, supervision, and critical review of the manuscript draft. However, he was not involved in the data analysis or interpretation. We have no other conflicts of interest to declare. Chinmanat Lekhavat, Jinda Rojanamatin, and Mingkwan Suphannaphong have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Ethics Committee\/Institutional Reviewer Board of the Institute of Dermatology, Bangkok, Thailand (approval no. 015\/2563). This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Written informed consent to participation was obtained from all participants. Written consent to publication was obtained from all participants whose images are included in the manuscript. The study was prospectively registered at ClinicalTrials.gov (registration no. NCT03926845).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"None of the participating patients were involved in the design, conduct, reporting, or dissemination plans for this research. However, all participants provided informed consent to participation prior to enrollment and were closely monitored throughout the study. Those whose images are shown in the figures also provided consent to the publication of this content. Their clinical outcomes and experiences of our participants were essential to the findings presented in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Involvement"}}]}}